On March 16, the CDE website showed that MSD'sBelzutifan Tablets Submitted for Marketing Approval in China; In February This Year, the Drug Was Granted Priority Review by the CDE, with the Indication for...von Hippel-LindVon Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastoma, or pancreatic neuroendocrine tumor (pNET).VHL is a rare hereditary disease, affecting 1 in 36,000 people.。VHL patients do notOnly at risk of developing benign vascular tumors, there is also a risk of developing certain cancers, including renal cell carcinoma.Belzutifan is a small-molecule hypoxia-inducible factor 2α (HIF-2α) inhibitor that reduces the transcription and expression of HIF-2α target genes associated with cell proliferation, angiogenesis, and tumor growth. In August 2021, Belzutifan received FDA accelerated approval based on Phase II clinical data.Approved for the treatment ofPatients with VHL-associated renal cell carcinoma, central nervous system hemangioblastoma, or pancreatic neuroendocrine tumors who do not require immediate surgery, becoming the world's first and currently only approved HIF-2α inhibitor.December 2023,Belzutifan Receives FDA Approval for Treatment AgainPatients with advanced renal cell carcinoma (RCC) who have received PD-(L)1 and anti-VEGF therapy。Copyright © 2024 PHARMCUBE. All Rights Reserved.Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article in a prominent position;For reprint, please leave a message or send a message to the WeChat Official Account backend, and indicate the name and ID of the official account.Disclaimer: The information in this WeChat article is for general reference only and should not be used directly as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.
↑ Long pressScan the code, Register for the Salon ↑
Approval will be notified by SMS.
